Warren Michael J.
Warren Michael J.'s purchase track record
How the stock did after each of Warren Michael J.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/28/2025 | MMS | $1K | -11.8% | -27.3% | +10.7% |
| 8/29/2025 | MMS | $1K | -1.7% | -13.3% | +6.5% |
| 5/30/2025 | MMS | $1K | +21.7% | +19.6% | +15.9% |
| 2/28/2025 | MMS | $1K | +11.7% | +35.9% | +8.5% |
| 11/29/2024 | MMS | $1K | -12.1% | -1.8% | -2.0% |
| 9/3/2024 | MMS | $1K | -17.2% | -24.8% | +4.5% |
| 5/31/2024 | MMS | $1K | +7.5% | -12.8% | +14.3% |
| 2/29/2024 | MMS | $603 | +2.1% | +11.2% | +9.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
KBW Lowers Walker & Dunlop Price Target to $45 Amid Rate Concerns. Keefe, Bruyette & Woods lowered its price target for Walker & Dunlop to $45 while maintaining an Outperform rating. This follows recent commentary from the company suggesting interest rates may have peaked, though data center growth raises concerns. The stock currently trades near its 52-week low, reflecting broader volatility in real estate capital markets.
Transaction History
| MMS | ▲ Buy | Grant | 2,246 | $0 | 3/10/2026 | View on chart |
| MMS | ▲ Buy | Grant | 39 | $0 | 12/1/2025 | View on chart |
| MMS | ▲ Buy | Open Market | 14 | $1K | 11/28/2025 | View on chart |
| MMS | ▲ Buy | Grant | 39 | $0 | 8/31/2025 | View on chart |
| MMS | ▲ Buy | Open Market | 14 | $1K | 8/29/2025 | View on chart |
| MMS | ▲ Buy | Grant | 47 | $0 | 5/31/2025 | View on chart |
| MMS | ▲ Buy | Open Market | 17 | $1K | 5/30/2025 | View on chart |
| MMS | ▲ Buy | Grant | 2,187 | $0 | 3/11/2025 | View on chart |
| MMS | ▲ Buy | Open Market | 18 | $1K | 2/28/2025 | View on chart |
| MMS | ▲ Buy | Open Market | 17 | $1K | 11/29/2024 | View on chart |
| MMS | ▲ Buy | Open Market | 13 | $1K | 9/3/2024 | View on chart |
| MMS | ▲ Buy | Open Market | 14 | $1K | 5/31/2024 | View on chart |
| MMS | ▲ Buy | Open Market | 7 | $603 | 2/29/2024 | View on chart |
| MMS | ▼ Sell | Open Market | 1,880 | $150K | 9/15/2023 | View on chart |
| MMS | ▼ Sell | Open Market | 2,490 | $198K | 8/16/2023 | View on chart |
| WD | ▼ Sell | Other | 2 | $315 | 3/8/2022 | View on chart |
| WD | ▼ Sell | Other | 2 | $262 | 11/24/2021 | View on chart |
| WD | ▼ Sell | Other | 2 | $261 | 9/1/2021 | View on chart |
| WD | ▼ Sell | Other | 3 | $259 | 6/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Maximus Shifts Earnings Focus to Defense and Medicaid
Maximus is moving its earnings mix away from VA incentives toward defense and Medicaid contracts, as discussed in a recent Yahoo article. A ChartMill piece highlighted the company’s strong cash flow and low valuation. The Q3 2026 earnings call transcript provides further detail on the company’s strategy. These developments give insight into Maximus’s future revenue mix.
Maximus Shifts Earnings Focus to Defense and Medicaid. Maximus is moving its earnings mix away from VA incentives toward defense and Medicaid contracts, as discussed in a recent Yahoo article. A ChartMill piece highlighted the company’s strong cash flow and low valuation. The Q3 2026 earnings call transcript provides further detail on the company’s strategy. These developments give insight into Maximus’s future revenue mix.